C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus
- PMID: 17531663
- DOI: 10.1016/j.jacc.2007.02.052
C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus
Abstract
Over 20 large-scale prospective studies show that the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) is an independent predictor of future cardiovascular events that additionally predicts risk of incident hypertension and diabetes. In many studies, the relative impact of hsCRP is at least as large as that individually of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure, or smoking, and knowledge of hsCRP correctly reclassifies a substantial proportion of "intermediate-risk" individuals into clinically relevant higher- or lower-risk categories. Other studies show the relative benefit of statins to be greater among those with increased hsCRP and that achieved hsCRP levels after statin therapy predict recurrent event rates as much as achieved levels of low-density lipoprotein cholesterol. Nonetheless, it remains controversial whether the time has come to modify traditional algorithms used for global risk detection. As described here, 6 areas of controversy regarding hsCRP are resolvable with a consensus position that focuses in primary prevention on selective use among individuals with 5% to 20% 10-year risk as estimated by Adult Treatment Panel III, and focuses in secondary prevention on high-risk patients being treated with statin therapy. Forthcoming trial data could expand or contract this "screen selectively" policy, and investigators should be open to the possibility that second-generation inflammatory biomarkers may be developed that supplant hsCRP altogether. In the meantime, however, this consensus position on hsCRP should be one to which both advocates and critics of the inflammatory hypothesis of atherosclerosis can adhere because it is one that can immediately improve patient care.
Similar articles
-
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1. Am J Cardiol. 2006. PMID: 16442935 Review.
-
Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.Int J Cardiol. 2005 Feb 15;98(2):199-206. doi: 10.1016/j.ijcard.2004.05.019. Int J Cardiol. 2005. PMID: 15686768 Review.
-
High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.J Am Coll Cardiol. 2007 May 29;49(21):2139-41. doi: 10.1016/j.jacc.2007.04.007. Epub 2007 Apr 30. J Am Coll Cardiol. 2007. PMID: 17531664 Review.
-
Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?Can J Cardiol. 2004 Aug;20 Suppl B:89B-92B. Can J Cardiol. 2004. PMID: 15309211 Review.
-
High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?Int Angiol. 2003 Mar;22(1):15-23. Int Angiol. 2003. PMID: 12771851 Review.
Cited by
-
Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease.Clin Res Cardiol. 2024 May 13. doi: 10.1007/s00392-024-02458-7. Online ahead of print. Clin Res Cardiol. 2024. PMID: 38740723
-
Medical comorbidities in bipolar disorder (BIPCOM): clinical validation of risk factors and biomarkers to improve prevention and treatment. Study protocol.Int J Bipolar Disord. 2024 May 4;12(1):15. doi: 10.1186/s40345-024-00337-8. Int J Bipolar Disord. 2024. PMID: 38703295 Free PMC article.
-
Obesity: An Impact with Cardiovascular and Cerebrovascular Diseases.Indian J Clin Biochem. 2024 Apr;39(2):168-178. doi: 10.1007/s12291-023-01157-w. Epub 2023 Oct 13. Indian J Clin Biochem. 2024. PMID: 38577137 Review.
-
Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease.Curr Cardiol Rep. 2024 Jun;26(6):483-495. doi: 10.1007/s11886-024-02050-5. Epub 2024 Apr 3. Curr Cardiol Rep. 2024. PMID: 38568339 Review.
-
The associations of health behaviors and working hours with high-sensitivity C-reactive protein levels in Korean wage workers: a cross-sectional study.Osong Public Health Res Perspect. 2023 Oct;14(5):356-367. doi: 10.24171/j.phrp.2023.0052. Epub 2023 Sep 21. Osong Public Health Res Perspect. 2023. PMID: 37920893 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials